Analysts expect Entellus Medical Inc (NASDAQ:ENTL) to announce earnings of ($0.45) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Entellus Medical’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.45). Entellus Medical posted earnings per share of ($0.39) in the same quarter last year, which indicates a negative year over year growth rate of 15.4%. The company is expected to announce its next earnings results on Tuesday, February 20th.

On average, analysts expect that Entellus Medical will report full year earnings of ($1.33) per share for the current year. For the next financial year, analysts forecast that the business will post earnings of ($1.42) per share, with EPS estimates ranging from ($1.64) to ($1.15). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entellus Medical.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings results on Wednesday, November 1st. The medical technology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.02. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 47.37%.

A number of analysts have commented on the stock. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. BidaskClub lowered shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a report on Tuesday. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday. William Blair lowered shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th. Finally, ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $19.25.

In other news, VP Kevin L. Mensink sold 2,500 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $19.00, for a total value of $47,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian E. Farley sold 101,319 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total transaction of $2,416,458.15. The disclosure for this sale can be found here. Insiders sold a total of 111,442 shares of company stock valued at $2,647,158 in the last three months. 7.70% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors grew its holdings in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock valued at $168,000 after buying an additional 5,605 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Entellus Medical by 74.7% in the 3rd quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock valued at $209,000 after buying an additional 4,846 shares during the period. Kopp Investment Advisors LLC grew its holdings in shares of Entellus Medical by 0.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after buying an additional 55 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after buying an additional 4,533 shares during the period. 78.24% of the stock is owned by institutional investors.

Shares of Entellus Medical (NASDAQ ENTL) opened at $24.09 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a market cap of $618.89, a price-to-earnings ratio of -18.67 and a beta of 0.02.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/18/entellus-medical-inc-entl-expected-to-announce-earnings-of-0-45-per-share.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.